US2020085804A1PendingUtilityA1

Agent for treating or preventing glaucoma including a sulfonamide compound and another drug

73
Assignee: SANTEN PHARMACEUTICAL CO LTDPriority: Jul 13, 2012Filed: Sep 23, 2019Published: Mar 19, 2020
Est. expiryJul 13, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Tomoko KiriharaAtsushi ShimazakiMasatsugu Nakamura
A61K 31/4178A61K 31/5377A61K 31/551A61K 31/5575A61K 45/06A61K 31/225A61K 31/542A61K 31/498C07D 401/14A61K 31/444
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition for preventing or treating glaucoma or ocular hypertension including a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl} pyridin-2-ylamino) acetate and at least one other drug for preventing or treating glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A preventive or therapeutic agent for glaucoma or ocular hypertension, comprising a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded. 
     
     
         2 . The preventive or therapeutic agent according to  claim 1 , wherein the other preventive or therapeutic drug for glaucoma or ocular hypertension is one or more preventive or therapeutic agents selected from the group consisting of a nonselective sympathomimetic drug, an α 2 -receptor agonist, an α 1 -receptor antagonist, a β-receptor antagonist, a parasympathomimetic drug, a carbonic anhydrase inhibitor, a prostaglandin and a Rho-kinase inhibitor. 
     
     
         3 . The preventive or therapeutic agent according to  claim 2 , wherein the nonselective sympathomimetic drug is dipivefrin. 
     
     
         4 . The preventive or therapeutic agent according to  claim 2 , wherein the α 2 -receptor agonist is brimonidine or apraclonidine. 
     
     
         5 . The preventive or therapeutic agent according to  claim 2 , wherein the α 1 -receptor antagonist is bunazosin. 
     
     
         6 . The preventive or therapeutic agent according to  claim 2 , wherein the β-receptor antagonist is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. 
     
     
         7 . The preventive or therapeutic agent according to  claim 2 , wherein the parasympathomimetic drug is pilocarpine. 
     
     
         8 . The preventive or therapeutic agent according to  claim 2 , wherein the carbonic anhydrase inhibitor is dorzolamide, brinzolamide or acetazolamide. 
     
     
         9 . The preventive or therapeutic agent according to  claim 2 , wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost. 
     
     
         10 . The preventive or therapeutic agent according to  claim 2 , wherein the Rho-kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl) benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine. 
     
     
         11 . An intraocular pressure lowering agent comprising a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded. 
     
     
         12 . The intraocular pressure lowering agent according to  claim 11 , wherein the other preventive or therapeutic drug for glaucoma or ocular hypertension is one or more preventive or therapeutic agents selected from the group consisting of a nonselective sympathomimetic drug, an α 2 -receptor agonist, an α 1 -receptor antagonist, a β-receptor antagonist, a parasympathomimetic drug, a carbonic anhydrase inhibitor, a prostaglandin and a Rho-kinase inhibitor. 
     
     
         13 . The intraocular pressure lowering agent according to  claim 12 , wherein the nonselective sympathomimetic drug is dipivefrin. 
     
     
         14 . The intraocular pressure lowering agent according to  claim 12 , wherein the α 2 -receptor agonist is brimonidine or apraclonidine. 
     
     
         15 . The intraocular pressure lowering agent according to  claim 12 , wherein the α 1 -receptor antagonist is bunazosin. 
     
     
         16 . The intraocular pressure lowering agent according to  claim 12 , wherein the β-receptor antagonist is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. 
     
     
         17 . The intraocular pressure lowering agent according to  claim 12 , wherein the parasympathomimetic drug is pilocarpine. 
     
     
         18 . The intraocular pressure lowering agent according to  claim 12 , wherein the carbonic anhydrase inhibitor is dorzolamide, brinzolamide or acetazolamide. 
     
     
         19 . The intraocular pressure lowering agent according to  claim 12 , wherein the prostaglandin is isopropyl unoprostone, latanoprost, travoprost or bimatoprost. 
     
     
         20 . The intraocular pressure lowering agent according to  claim 12 , wherein the Rho-kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl) benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Join the waitlist — get patent alerts

Track US2020085804A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.